Finzati - Logo
RPRX logo

Royalty Pharma plc

RPRX • Medical - Pharmaceuticals
$63.96
▲ +0.08 (+0.13%)
Current price
EarningsLatest report: Mar 31, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$23.81B
Growth
7.3%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 32.4%Positive free cash flow · 5.76Consistent free cash flow · 5/5Reasonable earnings multiple · 21.65Weak liquidity · 0.97
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 6, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$63.96
Change0.13%
Market Cap$23.81B
52W Range34.08 - 56.50
Beta0.44
Gross Margin100.00%
Oper. Margin65.58%
Profit Margin32.42%
Debt/Eq1.38
Current Ratio0.97
Quick Ratio0.97
Revenue 5Y7.30%

Investment DNA

How strong this company looks for long-term investors

75
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
53/100
Growth Potential
Revenue and expansion
43/100
Price Attractiveness
Cheap or expensive today
69/100
Why this score▼
Stable or improving margins · 32.4%Positive free cash flow · 5.76Consistent free cash flow · 5/5Reasonable earnings multiple · 21.65Weak liquidity · 0.97

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-06-24
Low
$50.00
Mean
$56.67
Median
$57.00
High
$63.00

Company Overview

IPO: 6/16/2020
Industry: Medical - Pharmaceuticals
P/B i: 2.58
Debt / Equity i: 1.38
Operating Margin: 65.58%
Net Margin: 32.42%
ROE i: -
ROIC: -

Financial Health

Score11 / 20
Debt / Equity: 1.38
Current Ratio: 0.97
Quick Ratio: 0.97
Status: Moderate

Warnings

  • Weak Liquidity

Insider Transactions

Recent executive and insider activity

Bassler Bonnie L
Transaction: 06/05/2026
BUY
Change
+4,545
Price
Not reported
Filing
06/08/2026
Type
BUY
Coric Vlad
Transaction: 06/05/2026
BUY
Change
+4,545
Price
Not reported
Filing
06/08/2026
Type
BUY
Engelbert Catherine M.
Transaction: 06/05/2026
BUY
Change
+4,545
Price
Not reported
Filing
06/08/2026
Type
BUY